Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 27, Issue 3, Pages 465-474Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458520921087
Keywords
Cladribine tablets; multiple sclerosis; MSBase registry; observational; disease-modifying drug; real world
Categories
Funding
- Merck KGaA, Darmstadt, Germany
Ask authors/readers for more resources
Clinical data from 90 cladribine-treated patients in the Australian MS registry showed a reduction in disability progression and relapse rates post-treatment. Approximately 80% were progression-free and 65% remained relapse-free after 2 years. Further clinical trials and comparative studies are needed to validate and extend these findings.
Background/objective: Observational clinical data from cladribine-treated patients with relapsing forms of multiple sclerosis (MS) were recorded in the Australian MS registry powered by the MSBase registry platform (5-year follow-up) and analysed to complement information from the pivotal cladribine clinical trials in MS. Methods: A cohort of 90 cladribine-treated patients with follow-up data reported by treating physicians and recorded in the Australian MSBase registry (database lock February 2016) were examined. Clinical data included Expanded Disability Status Scale (EDSS) scores, relapses and other disease-modifying drugs (DMDs) administered before and after cladribine treatment. Results: Mean age on starting cladribine was 47 years; mean age at MS onset was 34 years, and median baseline EDSS score was 5.25. Disability trajectories in patients with sufficient follow-up suggested an overall increasing trend prior to cladribine treatment which was reduced during the 2-year post-treatment. Approximately 80% of patients were EDSS progression-free, 65% remained relapse-free after 2 years and median time to next DMD was 1.7 years. Conclusion: These observational data suggest a disease-modifying effect in this cohort of relapsing MS patients characterised by older and more disabled patients. Since these data represent a single-arm cohort, clinical trials and larger comparative post-marketing studies are needed to validate and extend these findings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available